Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.53 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 19/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481454 | 1.00 | ITGB3 (0.53) | ITGB3ITGB1ITGAVITGA5ITGA4 | |
| SCHEMBL8337028 | 0.85 | F10 (0.49) | F10F2ABCB11ST14 | |
| SCHEMBL5473752 | 0.84 | F10 (0.62) | F10F2ABCB11ST14 | |
| SCHEMBL80174 | 0.82 | F10 (0.49) | F10F2ABCB11ST14 | |
| SCHEMBL3276611 | 0.82 | F10 (0.67) | F10F2ABCB11ST14 | |
| SCHEMBL2233431 | 0.82 | F10 (0.67) | F10F2ABCB11ST14 | |
| SCHEMBL78971 | 0.82 | F10 (0.67) | F10F2ABCB11ST14 | |
| SCHEMBL15326032 | 0.81 | F10 (0.47) | F10F2ABCB11ST14 | |
| SCHEMBL15326027 | 0.79 | F10 (0.47) | F10F2ABCB11ST14 | |
| SCHEMBL77633 | 0.78 | F10 (0.42) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066615-A1 | Heterocyclic compounds | BAYER HEATHCARE AG (DE) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066615-A1 | Heterocyclic compounds | F2, SERPINC1, TFPI | ITGB3 1676/4885ITGB1 2673/4885ITGAV 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.